Some Lessons From Participatory Evaluation of the COVID-19 Response in the African Region.

This summary report describes partners' experiences and reflections on responding to the COVID-19 pandemic in selected countries in the African Region. Using a common protocol for participatory evaluation and sensemaking, it communicates country partners' experiences with the COVID-19 response in Gabon, Kenya, and Senegal as well as a regional perspective from partners in the World Health Organization Regional Office for Africa (WHO AFRO). This report describes factors identified as associated with decreases (bending the curve) of new cases of COVID-19 over time, as well those associated with increases (worsening) of new cases, seen during the study period (2020-2021).

Giant cell tumor of the talus: A case report and literature review.

Introduction And Importance: Giant cell tumor is a benign primary bone tumor of mesenchymal origin that mainly affects the long bones. Involvement of the bones of the foot is rare with an incidence of 1 to 2 %. We report a case of giant cell tumor of the talus in a 36-year-old man.

Identifying populations at high risk of malaria: a mixed-methods case-control study to inform targeted interventions in Senegal.

Background: Senegal has made significant progress in reducing the burden of malaria, but transmission remains highly heterogeneous, with specific population subgroups likely at higher risk. Consultations with the National Malaria Control Programme (NMCP) and a review of available data identified nomadic pastoralists, gold miners, and Koranic school students as potential high-risk populations (HRPs). This study aimed to evaluate whether these populations are at higher risk of malaria and better characterize their exposure patterns to inform the design of targeted intervention strategies.

Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.

Background: Two pre-erythrocytic vaccines (R21/Matrix-M and RTS,S/AS01) are now approved for Plasmodium falciparum malaria. However, neither induces blood-stage immunity against parasites that break through from the liver. RH5.